Back to results
US 11,953,503 B2Granted
Method for quantitatively determining a therapeutic TNF-alpha inhibitor
AssigneeSiemens Healthcare Diagnostics Products GmbH
InventorsHarald Althaus, Thorsten Keller
Life of this patent
Estimating the term…
Abstract
Provided is a universal method for quantitatively determining therapeutic tumor necrosis factor (TNF)-alpha inhibitors in patient samples that is sufficiently sensitive for being able to detect all therapeutic TNF-alpha inhibitors.
Claims9
A method for quantitatively determining a therapeutic tumor necrosis factor (TNF)-alpha inhibitor in a sample, the method comprising the steps of:
- a) contacting the sample
- with isolated, free TNF-alpha protein to provide a reaction mixture;
- b) incubating the reaction mixture to allow binding of the isolated, free TNF-alpha protein to therapeutic TNF-alpha inhibitor in the sample;
- c) contacting the incubated reaction mixture with a first TNF-alpha binding partner to allow formation of a complex of isolated, free TNF-alpha protein remaining after step b) with the first TNF-alpha binding partner;
- d) determining the amount of the complex composed of TNF-alpha protein and the first TNF-alpha binding partner;
- and
- e) determining the amount of the therapeutic TNF-alpha inhibitor in the sample by comparing the amount of the complex composed of TNF-alpha protein and the first TNF-alpha binding partner determined in step d) with amounts of a complex composed of TNF-alpha protein and the first TNF-alpha binding partner in reaction mixtures containing samples having known concentrations of a TNF-alpha inhibitor.
4 more elements
Dependencies are inferred from the claim text.